Autor: Cedrych, Ida - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Advanced skin melanoma – systemic treatment
Autorzy:: Kruczała, Maksymilian
Ziobro, Marek
Grela-Wojewoda, Aleksandra
Cedrych, Ida
Powiązania:: https://bibliotekanauki.pl/articles/1065316.pdf
Data publikacji:: 2015
Wydawca:: Medical Education
Tematy:: immunotherapy
melanoma
systemic therapy
Opis:: In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
Źródło:: OncoReview; 2015, 5, 3; A133-138
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Complications of palliative antiangiogenic therapy in patients with colorectal cancer
Autorzy:: Domagała-Haduch, Małgorzata
Jasiówka, Marek
Nowak, Łukasz
Cedrych, Ida
Powiązania:: https://bibliotekanauki.pl/articles/1064817.pdf
Data publikacji:: 2016
Wydawca:: Medical Education
Tematy:: adverse effects
bevacizumab
colorectal cancer
treatment safety
Opis:: Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clinical trials. The scope of this paper is to analyze the safety profile of bevacizumab in patients with stage IV colorectal cancer. Aim of the study: Analysis of toxicity and safety of the treatment with bevacizumab patients with colorectal cancer in the metastatic stage. Material and methods: Retrospective analysis of medical records of 42 patients with advanced colorectal cancer treated in the Department of Systemic and Generalized Malignancies, Maria Skłodowska-Curie Memorial Institute of Oncology, Kraków Branch, in the period 2007–2014. Results: The median time of treatment with bevacizumab was 6 months. The median duration of progression-free survival (PFS) was 8.5 months. Toxicity of treatment with bevacizumab affected 43 percent of patients. The most common adverse events observed was hypertension and bleeding. In 6 patients (14.3%) the treatment with bevacizumab was interrupted due to adverse events (thromboembolic events, bleeding and gastrointestinal perforation). Conclusions: Bevacizumab is a safe therapeutic option in patients with metastatic colorectal cancer, provided that patients are provided close oncological and general medical monitoring.
Źródło:: OncoReview; 2016, 6, 4; A199-204
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: Everolimus – effectively reverses acquired resistance on endocrine therapy of patients with advanced breast cancer. A case report
Autorzy:: Grela-Wojewoda, Aleksandra
Kruczała, Maksymilian
Cedrych, Ida
Powiązania:: https://bibliotekanauki.pl/articles/1065382.pdf
Data publikacji:: 2014
Wydawca:: Medical Education
Tematy:: breast cancer
endocrine therapy
everolimus
Opis:: Breast cancer is the most common malignancy among women in Poland. Endocrine therapy is the first line of treatment in hormone-receptor-positive advanced breast cancer. Progression during endocrine therapy is unavoidable. Administration of mTOR inhibitor gives a chance of reversing the acquired resistance. This paper presents a case report of a patient with metastatic breast cancer successfully treated with everolimus added to endocrine therapy.
Źródło:: OncoReview; 2014, 4, 3; A117-120
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "Cedrych, Ida" wg kryterium: Autor

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język